Britta Weigelt

Summary

Affiliation: Cancer Research UK
Country: UK

Publications

  1. doi Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type
    Britta Weigelt
    Division of Experimental Therapy, The Netherlands Cancer Institute NKI, Amsterdam, The Netherlands
    Mod Pathol 22:1401-14. 2009
  2. pmc Prognostic signatures in breast cancer: correlation does not imply causation
    Charlotte Ng
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK
    Breast Cancer Res 14:313. 2012
  3. pmc Functional characterization of the 19q12 amplicon in grade III breast cancers
    Rachael Natrajan
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res 14:R53. 2012
  4. pmc HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment
    Britta Weigelt
    Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Mailstop 977R225A, 1 Cyclotron Road, Berkeley, CA 94720, USA
    Breast Cancer Res Treat 122:35-43. 2010
  5. pmc Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction
    Pierre Emmanuel Colombo
    Molecular Pathology Team, Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Breast Cancer Res 13:212. 2011
  6. doi Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type
    Magali Lacroix-Triki
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 222:282-98. 2010
  7. pmc Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement
    Alan Mackay
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Rd, London SW3 6JB, UK
    J Natl Cancer Inst 103:662-73. 2011
  8. doi A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers
    Rachael Natrajan
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK
    J Pathol 227:29-41. 2012
  9. doi Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers
    Daniel Wetterskog
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    J Pathol 226:84-96. 2012
  10. doi Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas
    Maria A Lopez-Garcia
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 222:64-75. 2010

Collaborators

Detail Information

Publications31

  1. doi Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type
    Britta Weigelt
    Division of Experimental Therapy, The Netherlands Cancer Institute NKI, Amsterdam, The Netherlands
    Mod Pathol 22:1401-14. 2009
    ..These findings support the contention that mucinous B and neuroendocrine carcinomas are part of a spectrum of lesions, whereas mucinous A is a discrete entity...
  2. pmc Prognostic signatures in breast cancer: correlation does not imply causation
    Charlotte Ng
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK
    Breast Cancer Res 14:313. 2012
    ..These findings demonstrate that a statistical association between a gene signature and disease outcome does not necessarily imply biological significance...
  3. pmc Functional characterization of the 19q12 amplicon in grade III breast cancers
    Rachael Natrajan
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res 14:R53. 2012
    ..The aim of this study was to identify the genes within the 19q12 amplicon whose expression is required for the survival of cancer cells harbouring their amplification...
  4. pmc HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment
    Britta Weigelt
    Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Mailstop 977R225A, 1 Cyclotron Road, Berkeley, CA 94720, USA
    Breast Cancer Res Treat 122:35-43. 2010
    ....
  5. pmc Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction
    Pierre Emmanuel Colombo
    Molecular Pathology Team, Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Breast Cancer Res 13:212. 2011
    ..Here, we review the clinical relevance of microarray-based profiling of breast cancer and discuss its impact on patient management...
  6. doi Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type
    Magali Lacroix-Triki
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 222:282-98. 2010
    ..Both components of mixed mucinous tumours are remarkably similar at the molecular level to pure mucinous cancers, suggesting that mixed mucinous carcinomas may be best classified as variants of mucinous cancers rather than of IDC-NSTs...
  7. pmc Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement
    Alan Mackay
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Rd, London SW3 6JB, UK
    J Natl Cancer Inst 103:662-73. 2011
    ..The aim of this study was to determine the objectivity and interobserver reproducibility of the assignment of molecular subtype classes by hierarchical cluster analysis...
  8. doi A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers
    Rachael Natrajan
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK
    J Pathol 227:29-41. 2012
    ....
  9. doi Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers
    Daniel Wetterskog
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    J Pathol 226:84-96. 2012
    ..Breast AdCCs constitute an entity distinct from grade-matched and triple-negative and basal-like IDC-NSTs, emphasizing the importance of histological subtyping of triple-negative and basal-like breast carcinomas...
  10. doi Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas
    Maria A Lopez-Garcia
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 222:64-75. 2010
    ....
  11. doi Breast cancer molecular profiling with single sample predictors: a retrospective analysis
    Britta Weigelt
    Cancer Research UK, London Research Institute, London, UK
    Lancet Oncol 11:339-49. 2010
    ..Three microarray-based single sample predictors (SSPs) have been used to define molecular classification of individual samples. We aimed to establish agreement between these SSPs for identification of breast cancer molecular subtypes...
  12. pmc Absence of microsatellite instability in mucinous carcinomas of the breast
    Magali Lacroix-Triki
    Molecular Pathology Team, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK
    Int J Clin Exp Pathol 4:22-31. 2010
    ..Our results demonstrate that MSI-high phenotype is remarkably rare in invasive breast cancer, and that, in contrast to mucinous carcinomas of other anatomical sites, MSI is not a common event in mucinous carcinomas of the breast...
  13. doi Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis
    Felipe C Geyer
    Molecular Pathology Team, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    Histopathology 60:E115-30. 2012
    ..The aims of this study were to determine whether MGAs harbour genetic alterations and if any such genetic aberrations found in MGAs are similar to those found in matched invasive carcinomas...
  14. doi Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection
    Lucia Hernandez
    Molecular Pathology Team, Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 227:42-52. 2012
    ....
  15. doi Immunophenotypic and genomic characterization of papillary carcinomas of the breast
    Raphaëlle Duprez
    Molecular Pathology Team, Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 226:427-41. 2012
    ..Furthermore, the good prognosis of papillary carcinomas may stem from the low rates of lymph node metastasis and p53 expression, low number of gene copy number aberrations and high prevalence of PIK3CA mutations...
  16. doi An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers
    Rachael Natrajan
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK
    Breast Cancer Res Treat 121:575-89. 2010
    ..g. proliferation, HER2 and ER signalling) may be driven by specific patterns of copy number aberrations...
  17. doi Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer
    Marleen Kok
    Departments of Pathology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    J Pathol 218:316-26. 2009
    ....
  18. doi Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis
    Britta Weigelt
    Life Sciences Division, Ernest Orlando Lawrence Berkeley National Laboratory, 1 Cyclotron Road, MS 977 225A, Berkeley, CA 94720, USA
    Breast Cancer Res Treat 117:273-80. 2009
    ..Previous histopathological and immunohistochemical analysis of MBCs suggested that these cancers would have a basal-like profile...
  19. pmc Unraveling the microenvironmental influences on the normal mammary gland and breast cancer
    Britta Weigelt
    Life Sciences Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, MS 977 225A, Berkeley, CA 94720, USA
    Semin Cancer Biol 18:311-21. 2008
    ....
  20. doi Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas
    Felipe C Geyer
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 220:562-73. 2010
    ..This proof-of-principle study provides direct evidence of intra-tumour genetic heterogeneity in breast cancers, and shows that in some cases morphological diversity may be underpinned by distinct genetic aberrations...
  21. doi Molecular profiling: moving away from tumor philately
    Jorge S Reis-Filho
    Molecular Pathology Laboratory, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK
    Sci Transl Med 2:47ps43. 2010
    ..On the wave of recent scientific advances and clinical findings, new cutting-edge technologies are poised to deliver an array of diverse molecular data that are expected to dramatically alter breast cancer diagnosis and treatment...
  22. doi The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade
    Britta Weigelt
    Signal Transduction Laboratory, Cancer Research UK, London Research Institute, London, UK
    J Pathol 220:263-80. 2010
    ..Here we endeavour to provide a fair and balanced assessment of what microarray-based gene expression analysis has taught us in the last decade and its contribution to breast cancer classification, prognostication and prediction...
  23. pmc Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
    Konstantin J Dedes
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    Cell Cycle 10:1192-9. 2011
    ..Here we discuss the evidence that the clinical use of PARP inhibition may be broader than targeting of cancers in BRCA1/2 germ-line mutation carriers...
  24. doi Genomic profiling of histological special types of breast cancer
    Hugo M Horlings
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Breast Cancer Res Treat 142:257-69. 2013
    ....
  25. ncbi Breast cancer metastasis: markers and models
    Britta Weigelt
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Nat Rev Cancer 5:591-602. 2005
    ..These data have important implications for prognosis prediction and our understanding of metastasis...
  26. doi Histological and molecular types of breast cancer: is there a unifying taxonomy?
    Britta Weigelt
    Cancer Research UK London Research Institute, Lincoln s Inn Fields Laboratories, London, UK
    Nat Rev Clin Oncol 6:718-30. 2009
    ....
  27. doi Molecular targets and targeted therapeutics in endometrial cancer
    Britta Weigelt
    Cancer Research UK London Research Institute, London, UK
    Curr Opin Oncol 24:554-63. 2012
    ..This review describes the molecular alterations in endometrial cancer and how this knowledge is leading to the development of novel treatments in this area...
  28. doi Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
    Martin D Forster
    Drug Development Unit, Royal Marsden Hospital, Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Nat Rev Clin Oncol 8:302-6. 2011
    ..She had received several lines of chemotherapy for multiple relapses over 9 years and displayed a profound sensitivity to platinum-containing regimens...
  29. doi Molecular classification of estrogen receptor-positive/luminal breast cancers
    Felipe C Geyer
    Department of Pathology, Hospital Israelita Albert Einstein, Instituto Israelita de Ensino e Pesquisa, Sao Paulo, Brazil
    Adv Anat Pathol 19:39-53. 2012
    ....
  30. ncbi Detection of circulating breast tumor cells by differential expression of marker genes
    Astrid J Bosma
    Division of Experimental Therapy, Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Clin Cancer Res 8:1871-7. 2002
    ..We undertook a systematic approach to identify breast cancer (BC) marker genes with molecular assays and evaluated these marker genes for the detection of minimal residual disease in peripheral blood mononuclear cells (PBMCs)...
  31. ncbi Hard-wired genotype in metastatic breast cancer
    Britta Weigelt
    The Netherlands Cancer Institute, Department of Experimental Therapy, Amsterdam, The Netherlands
    Cell Cycle 3:756-7. 2004
    ..Our findings challenge this common theory and imply that the metastatic nature of 'poor prognosis profile' breast carcinomas is an inherent feature, and not reserved to advantageous subpopulations...